Skip to main content
Signal8
Launch Terminal

ENANTA PHARMACEUTICALS INC (ENTA)

Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Enanta Pharmaceuticals, Inc. logo

Enanta Pharmaceuticals, Inc.

NASDAQ:ENTAHealthcare
-3.95%$10.71
AH$10.71+0.00%vs close
Mkt Cap$311.93M
Float27.48M
O/S29.13M
Vol
$ Vol
RVOL
Inst Own93.6%
Earnings
Dilution
Enanta Pharmaceuticals, Inc. logoNASDAQ:ENTA$10.71-3.95%
Upcoming Catalysts
Phase Distribution
45 lead-sponsored trials·2 active·38 completed
Phase 133
Phase 212

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Status
Phase
  • Phase 2
    Unknown status

    Comparative Study of EDP-420 Versus Another Antibiotic in the Treatment of Community Acquired Pneumonia

    EDP-420 / Duration of Treatment - 3 days, Telithromycin / Duration of Treatment - 7 days

    Community Acquired Pneumonia

    Enrollment
    250
    Start
    Dec 2005
    Primary Completion
    -
    Completion
    Jul 2007
    NCT00270517
  • Phase 2
    Completed

    A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis

    EDP-305 1 mg, EDP-305 2.5 mg

    Primary Biliary Cholangitis

    Enrollment
    68
    Start
    Dec 2017
    Primary Completion
    Dec 2019
    Completion
    Jan 2020
    NCT03394924
  • Phase 2
    Completed

    A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis

    EDP-305 Dose 1, EDP-305 Dose 2

    Non-Alcoholic Steatohepatitis

    Enrollment
    134
    Start
    Apr 2018
    Primary Completion
    Jun 2019
    Completion
    Jul 2019
    NCT03421431
  • Phase 2
    Completed

    A Phase 2a Study to Evaluate EDP-938 in the Virus Challenge Model

    EDP-938 Dose 1, EDP-938 Dose 2

    RSV Infection

    Enrollment
    179
    Start
    Oct 2018
    Primary Completion
    Sep 2019
    Completion
    Oct 2019
    NCT03691623
  • Phase 2
    Completed

    A Study to Assess EDP-938 for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Adult Subjects

    EDP-938, Placebo

    Respiratory Syncytial Virus

    Enrollment
    82
    Start
    Jan 2020
    Primary Completion
    Jan 2022
    Completion
    Jan 2022
    NCT04196101
  • Phase 2
    Terminated

    A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH

    EDP-305 1.5 mg, EDP-305 2 mg

    Non-Alcoholic Steatohepatitis

    Enrollment
    98
    Start
    Jan 2020
    Primary Completion
    Oct 2021
    Completion
    Nov 2021
    NCT04378010
  • Phase 2
    Terminated

    Effects of EDP-938 in Hematopoietic Cell Transplant Recipients Infected With Respiratory Syncytial Virus of the Upper Respiratory Tract

    EDP-938, Placebo

    Respiratory Syncytial Virus Infections

    Enrollment
    9
    Start
    Jul 2021
    Primary Completion
    May 2023
    Completion
    May 2023
    NCT04633187
  • Phase 2
    Completed

    A Study to Evaluate EDP 938 Regimens in Children With RSV

    EDP-938, Placebo

    Respiratory Syncytial Virus (RSV)

    Enrollment
    99
    Start
    Apr 2022
    Primary Completion
    Aug 2024
    Completion
    Aug 2024
    NCT04816721
  • Phase 2
    Completed

    A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.

    EDP-938, Placebo

    RSV Infection

    Enrollment
    187
    Start
    Nov 2022
    Primary Completion
    Jun 2025
    Completion
    Jun 2025
    NCT05568706
  • Phase 2
    Completed

    A Study to Evaluate EDP-235 in Non-hospitalized Adults With COVID-19

    EDP-235, Placebo

    COVID-19

    Enrollment
    231
    Start
    Nov 2022
    Primary Completion
    Feb 2023
    Completion
    Jun 2023
    NCT05616728
  • Phase 2
    Completed

    A Controlled Phase 2a Study to Evaluate the Efficacy of EDP-323 Against Respiratory Syncytial Virus Infection in a Virus Challenge Model

    EDP-323 Dose Regimen 1, EDP-323 Dose Regimen 2

    RSV Infection

    Enrollment
    142
    Start
    Nov 2023
    Primary Completion
    Jun 2024
    Completion
    Jul 2024
    NCT06170242
  • Phase 2
    Recruiting

    A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus

    zelicapavir, Placebo

    RSV Infection, RSV +1

    Enrollment
    150
    Start
    Jul 2026
    Primary Completion
    Dec 2026est.
    Completion
    Dec 2026est.
    NCT07482657
  • Phase 1
    Completed

    Safety and Pharmacokinetics of Ascending Single Oral Doses of EDP-322 in Nonfasting and Fasting Healthy Volunteers

    EDP-322

    Skin and Soft Tissue Infections, Methicillin-resistant Staphylococcus Aureus

    Enrollment
    67
    Start
    -
    Primary Completion
    -
    Completion
    -
    NCT00989872
  • Phase 1
    Completed

    Multiple Ascending-Dose Study of EDP 322 in Healthy Adult Volunteers

    EDP-322

    MRSA, SSTI

    Enrollment
    52
    Start
    Nov 2008
    Primary Completion
    Mar 2009
    Completion
    Sep 2009
    NCT00990145
  • Phase 1
    Completed

    Proof of Concept Study for Safety and Efficacy of EDP239 in Hepatitis C Subjects

    EDP239, Placebo

    Hepatitis C

    Enrollment
    28
    Start
    Jun 2013
    Primary Completion
    Nov 2014
    Completion
    Oct 2015
    NCT01856426
  • Phase 1
    Completed

    Evaluation of the Safety and Pharmacokinetics of a Single Oral Dose of EDP-788

    EDP-788, Placebo

    Safety in Normal Volunteers

    Enrollment
    80
    Start
    Jan 2014
    Primary Completion
    Sep 2014
    Completion
    Sep 2014
    NCT01999725
  • Phase 1
    Completed

    Two-way Interaction Between Alisporivir and EDP239

    DEB025, EDP239

    Hepatitis C Virus

    Enrollment
    42
    Start
    Aug 2014
    Primary Completion
    Nov 2014
    Completion
    Nov 2014
    NCT02173574
  • Phase 1
    Terminated

    Evaluation of the Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of EDP-788

    EDP-788, Placebo

    Healthy

    Enrollment
    16
    Start
    Aug 2014
    Primary Completion
    Oct 2014
    Completion
    Oct 2014
    NCT02255968
  • Phase 1
    Completed

    EDP-494-001: A Study of EDP-494 in Healthy Subjects and Hepatitis C Patients

    EDP-494, Placebo

    Hepatitis C

    Enrollment
    100
    Start
    Jan 2016
    Primary Completion
    Dec 2016
    Completion
    Dec 2016
    NCT02652377
  • Phase 1
    Completed

    A Study of EDP 305 in Healthy Subjects and Subjects With Presumptive NAFLD

    EDP 305, Placebo

    Presumptive NAFLD

    Enrollment
    146
    Start
    Sep 2016
    Primary Completion
    Jun 2017
    Completion
    Jun 2017
    NCT02918929
  • Phase 1
    Completed

    Drug-drug Interaction Study Between EDP-305, Midazolam, Caffeine and Rosuvastatin in Healthy Volunteers.

    Midazolam, Caffeine

    NASH

    Enrollment
    24
    Start
    May 2017
    Primary Completion
    Jun 2017
    Completion
    Jun 2017
    NCT03187496
  • Phase 1
    Completed

    A Study of EDP-305 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers

    EDP 305

    NASH

    Enrollment
    29
    Start
    Jun 2017
    Primary Completion
    Sep 2017
    Completion
    Sep 2017
    NCT03207425
  • Phase 1
    Completed

    Drug-drug Interaction Study Between EDP-305, Intraconazole and Rifampin in Healthy Volunteers

    intraconazole, Rifampin

    NASH - Nonalcoholic Steatohepatitis

    Enrollment
    48
    Start
    Jul 2017
    Primary Completion
    Aug 2017
    Completion
    Sep 2017
    NCT03213145
  • Phase 1
    Completed

    A Study of EDP-938 in Healthy Subjects

    EDP-938, Placebo

    RSV Infection

    Enrollment
    90
    Start
    Dec 2017
    Primary Completion
    Jul 2018
    Completion
    Jul 2018
    NCT03384823
  • Phase 1
    Completed

    Drug-drug Interaction Study Between EDP-305, Fluconazole and Quinidine in Healthy Volunteers

    Fluconazole, Quinidine

    NASH - Nonalcoholic Steatohepatitis

    Enrollment
    48
    Start
    Jul 2018
    Primary Completion
    Aug 2018
    Completion
    Aug 2018
    NCT03610945

1-25 of 45

Search ClinicalTrials.gov for “Enanta Pharmaceuticals”